Skip to main content
. 2022 May 24;57(8):1295–1303. doi: 10.1038/s41409-022-01705-7

Table 2.

All adverse events by grade and treatment group.

SAE Flu-Bu (N = 130) FCB_(N = 120)
Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 ALL Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 ALL
Mucositis 27 67 25 0 0 119 29 67 19 0 0 115
VOD/SOS 0 0 0 0 0 0 0 0 2 0 1 3
Elevated Bilirubin 10 25 7 0 0 42 10 32 6 1 0 49
PRES 0 0 1 0 0 1 0 0 3 0 0 3
DAH 0 0 0 0 2 2 0 0 0 1 1 2
Pneumonitis 0 0 5 0 1 6 0 0 3 1 1 5
Hand/Foot Syndrome 6 5 0 0 0 11 6 4 1 0 0 11
Infection: Bacterial 13 5 11 3 1 33 3 4 21 3 6 37
Infection: Viral 9 55 4 1 2 71 10 33 9 0 3 55
Infection: Fungal 0 0 2 2 2 6 0 0 4 2 3 9

SAE Serious Adverse Events, VOD Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome, PRES Posterior Reversible Encephalopathy Syndrome, DAH diffuse alveolar hemorrhage.